Athenex, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (19)

View All

Latest Posts

About This Stock More About This Stock
Athenex, Inc. Announces Pricing Of $110 Million Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire
Thursday, September 10, 2020 10:51 AM EDT
Athenex, Inc., today announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of $11.00 per share.
In this article: ATNX
Read
Week In Review: 2018 Results: China Life Science Investment Hits Record Levels
Article By: ChinaBio® Today
Saturday, January 5, 2019 4:28 PM EDT
Investments in China life science set new records in all categories during 2018, reflecting the increasing development of the industry. And these numbers are spectacular even in comparison to an already strong 2017.
In this article: NVCR, ATNX, ZLAB
Read
Week In Review: Suzhou Innovent Files For HK IPO -- $500 Million Raise Rumored
Article By: ChinaBio® Today
Saturday, July 7, 2018 4:06 PM EDT
Innovent Biologics of Suzhou has filed to IPO on the Hong Kong Exchange under its new rules for pre-revenue biopharmas. The company plans to raise as much as $500 million, according to media reports, at a valuation of over $1 billion.
In this article: LLY, SNY, SVA, BABA, ATNX
Read
Week In Review: Beigene Sets Record With $1.4 Billion Celgene Deal
Article By: ChinaBio® Today
Saturday, July 8, 2017 2:35 PM EDT
BeiGene of Beijing has entered a "transformational" collaboration with Celgene which involves BeiGene's clinical-stage PD-1 immuno-oncology drug, has a total value of almost $1.4 billion.
In this article: CELG, QGEN, BGNE, BYSI, ATNX
Read
Athenex: An Under-The-Radar Buying Opportunity
Article By: Don Dion
Monday, July 3, 2017 11:45 AM EDT
Athenex has performed well in early trading since its market debut. It has demonstrated growing revenues, and its underwriters chose to exercise their over-allotment options in full.
In this article: ATNX
Read
All Posts

Latest Tweets for $ATNX

No tweets yet!

PARTNER HEADLINES